One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Pharmacotherapy of LAMA/LABA inhaled therapy combinations for chronic obstructive pulmonary disease: a clinical overview
Maria Gabriella Matera, Barbara Rinaldi, Carmela Belardo & Mario Cazzola
doi : 10.1080/17512433.2022.2134113
Expert Review of Clinical Pharmacology, Volume 15, Issue 11 (2022)
Long-acting muscarinic receptor antagonist (LAMA)/β2-agonist (LABA) combinations represent a significant improvement in the treatment of chronic obstructive pulmonary disease (COPD) due to their remarkable ability to improve lung function, dyspnea, quality of life, and exercise capacity compared to mono-components.
Novel and emerging treatment strategies for lupus nephritis
Desmond Yat Hin Yap & Chi Chiu Mok
doi : 10.1080/17512433.2022.2138340
Lupus nephritis (LN) is a key predictor for kidney failure and death in patients with systemic lupus erythematosus. While conventional immunosuppressive treatments have improved the outcome of LN, novel therapies continue to emerge. These new agents targetspecific immune-reactive cells, cytokines and signaling pathways in LN pathogenesis.
The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations
Benjamin A. Teply & Emmanuel S. Antonarakis
doi : 10.1080/17512433.2022.2140656
PARP inhibition in prostate cancer has become a standard-of-care option for men with metastatic castration-resistant prostate cancer (mCRPC) with deficiency in homologous recombination repair (HRRd). The benefit varies based upon the characteristics of the PARP inhibitor used and the underlying HRR defect. Optimal patient selection remains a clinical challenge, and investigations are underway to identify effective combination therapies to expand the population that benefits.
Current understanding of the etiology of cyclic vomiting syndrome and therapeutic strategies in its management
Rosita Frazier & Thangam Venkatesan
doi : 10.1080/17512433.2022.2138341
Cyclic vomiting syndrome (CVS) is a chronic-debilitating disorder of the gut–brain interaction and is characterized by recurrent episodes of nausea and vomiting.
Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients
Madison M. Crutcher, Adam E. Snook & Scott A. Waldman
doi : 10.1080/17512433.2022.2138339
Colorectal cancer (CRC) is the second most common cause of cancer-related death worldwide. Although overall survival for CRC patients has improved with earlier screening, survival continues to vary substantially across stages.
Clinical pharmacology of siRNA therapeutics: current status and future prospects
Ahmed Khaled Abosalha, Jacqueline Boyajian, Waqar Ahmad, Paromita Islam, Merry Ghebretatios, Sabrina Schaly, Rahul Thareja, Karan Arora & Satya Prakash
doi : 10.1080/17512433.2022.2136166
Small interfering RNA (siRNA) has emerged as a powerful tool for post-transcriptional downregulation of multiple genes for various therapies. Naked siRNA molecules are surrounded by several barriers that tackle their optimum delivery to target tissues such as limited cellular uptake, short circulation time, degradation by endonucleases, glomerular filtration, and capturing by the reticuloendothelial system (RES).
Incidence and risk of severe adverse events associated with trastuzumab emtansine (T-DM1) in the treatment of breast cancer: an up-to-date systematic review and meta-analysis of randomized controlled clinical trials
Kuan Liu, Yan-Hong Li, Xi Zhang, Lei Su, Jing-Hua Li, Hong-Yun Shi & Jun-Hua Zhang
doi : 10.1080/17512433.2022.2121704
We performed an up-to-date meta-analysis to quantify the overall incidence and risk of severe adverse events (AEs) associated with T-DM1 in patients with breast cancer.
Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database
Zhuo Ma, Yi Zhang, Min Zhu, Lin Feng, Yuhui Zhang & Zhuoling An
doi : 10.1080/17512433.2022.2121705
Interstitial lung disease (ILD) events associated with anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates (ADCs) have aroused wide attention.
Effectiveness of polyene phosphatidylcholine and its combination with other drugs in patients with liver diseases based on real-world research
Ying Li, Anni Chen, Zhizhen Li, Xiuliang Cui & Guoqing Zhang
doi : 10.1080/17512433.2022.2121700
Polyene phosphatidylcholine (PPC) is a widely used hepatoprotective drug. We aim to explore the effectiveness of PPC in patients with liver diseases based on real-world research, and compare with other hepatoprotective drugs.
